Optipres Eye Drops (Betaxolol) - 0.5% w/v (5mL) Image1

Optipres Eye Drops

Betaxolol

* Our best price : $ 6.93

Optipres Eye Drops (Betaxolol) is an eye drop containing a selective beta-1 receptor blocker used to treat hypertension and reduce intraocular pressure associated with glaucoma.

Brand Name : Optipres Eye Drops
Active Ingredients : Betaxolol
Manufacturer : Cipla
Country of Origin : India
Intended Patient : Unisex
Optipres Eye Drops (Betaxolol) - 0.5% w/v (5mL) Optipres Eye Drops (Betaxolol) - 0.5% w/v (5mL) Image1
Out of stock
* Quantity
1 Bottle(s)
2 Bottle(s)
3-5 Bottle(s)
6 Bottle(s) +
Price / Each
$9.24
$8.72
$8.09
$6.93

Description


Uses

Optipres Eye Drops (Betaxolol) is a selective beta-1 receptor blocker used to treat hypertension and reduce intraocular pressure associated with glaucoma. It reduces elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. It does not have significant membrane stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Optipres Eye Drops is found to have minimal effect on pulmonary and cardiovascular parameters.

Dosage and Administration

For treatment of glaucoma, Optipres Eye Drops (Betaxolol) are usually applied twice daily. Intraocular pressure should be reassessed approximately 4 weeks after starting treatment because response to Optipres Eye Drops may take a few weeks to stabilise.

Side effects

Optipres Eye Drops (Betaxolol) may cause:

  • blurred vision
  • corneal punctate keratitis
  • foreign body sensation
  • photophobia
  • tearing
  • itching
  • dryness of eyes
  • erythema
  • ocular pain
  • decreased visual acuity
  • crusty lashes
  • dyspnea
  • bronchospasm
  • thickened bronchial secretions
  • bradycardia
  • dizziness
  • vertigo
  • headaches
Precautions

Patients who are receiving a beta-adrenergic blocking agent orally and Optipres Eye Drops (Betaxolol) should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockage. Patients should not receive two topical ophthalmic beta-adrenergic blocking agents concurrently.

Use with caution in patients with diabetes or in patients suspected of developing thyrotoxicosis.

This product is added. Thank you.

 Please choose your option:

0
My Cart : 0 Items $0.00

Shopping Cart

 

Your cart is empty